Zusammenfassung
Die chronische myeloische Leukämie (CML) ist eine lebensbedrohliche Erkrankung. Seit der Einführung des Tyrosinkinasehemmers Imatinib haben sich die Behandlungsaussichten bei CML jedoch entscheidend verbessert. Die Imatinibtherapie ist deutlich wirksamer als Hydroxyurea oder Interferon-α. Imatinib ist heute die Standardbehandlung in der Erstlinientherapie von CML-Patienten in chronischer Phase. Dennoch werden in Deutschland gemäß neuerer statistischer Erhebungen noch immer fast ein Drittel (25–32%) der CML-Patienten mit Hydroxyurea behandelt. Betroffen davon sind v. a. ältere CML-Patienten über 60 Jahre, denen eine Behandlung mit Imatinib vorenthalten wird. Verschiedene Studien haben belegt, dass Imatinib auch bei älteren CML-Patienten wirksam ist und allgemein gut vertragen wird. Dieser Bericht soll einen kritischen Überblick über bestehende Daten zur CML-Therapie bei älteren Patienten liefern und enthält Empfehlungen für die initiale Behandlung älterer CML-Patienten.
Abstract
Chronic myeloid leukemia (CML) is a life-threatening disease. The introduction of imatinib, a tyrosine kinase inhibitor, substantially improved the prognosis for long-term survival with CML. Imatinib is significantly more effective than hydroxyurea or interferon-α and is now established as the standard first-line therapy for CML patients in the chronic phase. Nevertheless, according to recent surveys, almost one-third (25–32%) of all CML patients in Germany are still being treated with hydroxyurea. Most of these are elderly CML patients >60 years old, from whom imatinib treatment is withheld on the basis of age. Various studies have shown that imatinib is also effective in elderly CML patients and is well tolerated. This report gives a critical review of existing data on the treatment of elderly CML patients with imatinib and contains recommendations for first-line therapy for patients in this age group.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Atallah E, Durand JB, Kantarjian H et al (2007) Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 110:1233–1237
Baccarani M, Saglio G, Goldman J et al (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809–1820
Cortes J, Talpaz M, O’Brien S et al (2003) Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 98:1105–1113
Deininger MWN, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343–3356
Druker BJ, Guilhot F, O’Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408–2417
Gratwohl A, Brand R, Apperley J et al (2006) Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 91:513–521
Gugliotta BG, Castagnetti F, Amabile M et al (2009) Age has no impact on outcome of early chronic phase, Ph-pos CML, imatinib treated patients: a nationwide analysis on 559 cases of the GIMEMA CML WP. Haematologica 94:256
Butscheid Y, Chang T, Schuld P (2008) Imatinib therapy in elderly CML patients: interim results of the ElderGli observational study. Onkologie 31 (Suppl 4):102
Hasford J, Pfirrmann M, Hehlmann R et al (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90:850–858
Hasford J, Tauscher M, Hochhaus A (2007) Incidence, Comorbidity and Treatment Survey of Chronic Myeoloid Leukemia in Germany. Blood. ASH Annual Meeting Abstracts 110:Abstract 2964
Hehlmann R, Heimpel H, Hasford J et al (1994) Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 84:4064–4077
Hehlmann R, Hochhaus A, Baccarani M (2007) Chronic myeloid leukaemia. Lancet 370:342–350
Horner M, Ries L, Krapcho M et al (2009) SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. In: Bethesda MD http://www.seer.cancer.gov/csr/1975_2006/
Kantarjian HM, Keating MJ, Mccredie KB et al (1987) Old age: a sign of poor prognosis in patients with chronic myelogenous leukemia. South Med J 80:1228–1232
Kantarjian HM, Larson RA, Guilhot F et al (2006) Declining Rates of Adverse Events (AEs), Rare Occurrence of Serious AEs (SAEs), and No Unexpected Long-Term Side Effects at 5 Years in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Initially Treated with Imatinib (IM) in the International Randomized Study of Interferon vs STI571 (IRIS).Blood. ASH Annual Meeting Abstracts 108:Abstract 2136
Kantarjian HM, O’Brien S, Cortes J et al (2003) Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 98:2636–2642
Küster P, Gfk_Healthcare (2007, 2008) Einsatz von Imatinib und HU bei älteren CML-Patienten. Statistische Erhebungen durch GfK Healthcare
Noens L, Van Lierde M-A, De Bock R et al (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113:5401–5411
O’Brien SG, Guilhot F, Goldman JM et al (2008) International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM). Blood. ASH Annual Meeting Abstracts 112:Abstract 186
O’brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994–1004
Pletsch N, Lauseker M, Saussele S et al (2009) Therapy with imatinib in elderly CML patients (≥65 years) is well tolerated but cytogenetic and molecular remissions seem to be achieved later compared to younger patients. Haematologica 94:253
Rosti G, Iacobucci I, Bassi S et al (2007) Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematologica 92:101–105
Rousselot P, Nicolini F, Mahon FX et al (2007) High Efficacy and Particular Safety Profile of Imatinib Mesylate (Glivec®) in Elderly Patients with CML in Chronic Phase: Results of the AFR04 Prospective Study. Blood. ASH Annual Meeting Abstracts 110:Abstract 1039
Silver RT, Woolf SH, Hehlmann R et al (1999) An Evidence-Based Analysis of the Effect of Busulfan, Hydroxyurea, Interferon, and Allogeneic Bone Marrow Transplantation in Treating the Chronic Phase of Chronic Myeloid Leukemia: Developed for the American Society of Hematology. Blood 94:1517–1536
Sokal JE, Cox EB, Baccarani M et al (1984) Prognostic discrimination in „good-risk“ chronic granulocytic leukemia. Blood 63:789–799
Interessenkonflikt
Der korrespondierende Autor weist auf folgende Beziehung/en hin: Alle Autoren erhielten Beraterhonorare für die Teilnahme an Advisory Board Meetings von Novartis. Die Manuskripterstellung wurde durch Novartis unterstützt.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hochhaus, A., Duyster, J., Haferlach, T. et al. Therapie der chronischen myeloischen Leukämie bei älteren Patienten. Onkologe 16, 67–72 (2010). https://doi.org/10.1007/s00761-009-1754-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00761-009-1754-5